Targeting KRASG12C in colorectal cancer: the beginning of a new era.

Abstract excerpt

RAS mutation is considered one of the most relevant oncogenic drivers in human cancers. Unfortunately, for more than three decades, RAS has been considered an undruggable target. Recently, the discovery of selective and potent KRASG12C inhibitors represented a light at the end of the tunnel. Indeed, sotorasib and adagrasib proved clinical activity in patients with refractory metastatic colorectal cancer harboring...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Colonic Neoplasms
• Share to Mutation
• Share to Penicillins